Mental Health & Parkinson's Disease

Mental health challenges are among the most common and disabling non-motor symptoms of Parkinson's disease. Depression affects an estimated 40% to 50% of people with Parkinson's, anxiety affects roughly 30% to 40%, and apathy is present in up to 40%. Cognitive changes, ranging from mild impairment to dementia, eventually affect the majority of people living with the disease. A 2025 review in Nature Reviews Neurology found that 24% to 31% of people with Parkinson's develop dementia, and 26% have mild cognitive impairment.

These symptoms are not simply emotional reactions to a difficult diagnosis — they are caused in large part by the same brain changes that produce the motor symptoms of Parkinson's. The loss of dopamine, serotonin, and norepinephrine in key brain circuits directly disrupts mood regulation, motivation, and cognitive function. Understanding this biology is important because it means these symptoms are treatable medical conditions, not personal weaknesses.

Depression

Depression in Parkinson's disease is clinically and neurobiologically distinct from typical major depressive disorder. A landmark review in Nature Reviews Neurology (2012) described how Parkinson's-related depression involves degeneration of multiple neurotransmitter systems — not just dopamine, but also serotonergic neurons in the raphe nuclei and noradrenergic neurons in the locus coeruleus. This multi-system disruption explains why Parkinson's depression often presents differently from typical depression.

People with Parkinson's-related depression tend to experience more irritability, anxiety, and sadness without the pervasive feelings of guilt and worthlessness that characterize typical depression. The symptoms can overlap significantly with Parkinson's itself — fatigue, sleep disruption, slowed movement, reduced facial expression (masking), and loss of interest can all look like depression, making diagnosis challenging. Studies estimate that depression in Parkinson's is underdiagnosed in up to 50% of cases.

Warning Signs

• Persistent sadness, emptiness, or hopelessness lasting more than two weeks
• Loss of interest or pleasure in activities you previously enjoyed
• Changes in appetite or weight unrelated to Parkinson's progression
• Withdrawal from social activities and relationships
• Difficulty concentrating or making decisions beyond what Parkinson's explains
• Increased irritability or emotional reactivity disproportionate to circumstances
• Thoughts of death or suicide — seek immediate help (call 988 or go to the nearest emergency room)

Treatment Approaches

• Antidepressant medications — SSRIs (selective serotonin reuptake inhibitors) such as sertraline and citalopram and SNRIs such as venlafaxine are commonly used. Your neurologist can recommend medications that do not interfere with your Parkinson's treatment. Important considerations: SSRIs and SNRIs may worsen REM sleep behavior disorder; mirtazapine and trazodone may be better alternatives if RBD is present. MAO-B inhibitors used for Parkinson's (selegiline, rasagiline) may also have mild antidepressant effects.
• Cognitive behavioral therapy (CBT) — Research supports CBT as an effective treatment for depression in Parkinson's, either alone or combined with medication. CBT is particularly helpful because it addresses the thought patterns specific to chronic illness — catastrophizing about progression, all-or-nothing thinking about disability, and social withdrawal.
• Exercise — The 2023 Cochrane review of 156 randomized controlled trials found that regular aerobic exercise has demonstrated antidepressant effects comparable to medication in mild to moderate depression. Resistance training may be particularly effective for improving quality of life and reducing emotional dysfunction.
• Dopaminergic medication adjustment — Depression often worsens during "off" periods when dopamine levels are low. Optimizing Parkinson's motor treatment can improve mood as a secondary benefit. Pramipexole (a dopamine agonist) has shown antidepressant properties in some studies, though it carries its own risks (see impulse control disorders below).
• Social engagement — Isolation worsens depression. Parkinson's support groups, exercise classes, and community activities provide both social connection and practical information. The Parkinson's Foundation operates local support groups throughout the United States.

Anxiety

Anxiety in Parkinson's affects 30% to 40% of patients and often goes hand in hand with motor fluctuations. Many people experience surges of anxiety during "off" periods when their medication is wearing off, and relief when the next dose takes effect. This pattern confirms that anxiety in Parkinson's has a significant neurochemical component, linked to the dopaminergic and noradrenergic system fluctuations that accompany medication cycles.

Common forms of anxiety in Parkinson's include:

• Generalized anxiety disorder — Persistent, excessive worry about disease progression, finances, burden on family, or daily functioning.
• Social anxiety — Particularly related to visible symptoms like tremor, slowness, speech changes, or drooling in public settings. Social anxiety can lead to progressive isolation.
• Panic attacks — Sudden episodes of intense fear with physical symptoms (racing heart, shortness of breath, dizziness). These often occur during medication "off" periods.
• Fear of falling — A form of situational anxiety that can become so debilitating that it prevents activity, paradoxically increasing fall risk through deconditioning.

Anxiety Management Strategies

• Work with your neurologist to smooth out medication cycles and reduce the duration and severity of "off" periods. Extended-release levodopa formulations can provide more consistent dopamine delivery.
• Mindfulness-based stress reduction (MBSR) and relaxation techniques have shown benefits in Parkinson's-specific studies. Even 10 to 15 minutes of daily mindfulness practice can reduce anxiety levels over time.
• Cognitive behavioral therapy tailored to the specific anxiety patterns of Parkinson's disease, addressing both the neurochemical and psychological components.
• Anti-anxiety medication when symptoms are severe, prescribed in consultation with your neurologist. Benzodiazepines should be used cautiously due to increased fall risk, cognitive effects, and potential for dependence. Buspirone may be a safer alternative for chronic anxiety.
• Regular exercise — the Cochrane evidence supports exercise for anxiety reduction alongside its antidepressant effects.

Apathy

Apathy — a loss of motivation, initiative, and emotional responsiveness — is one of the most underrecognized and undertreated symptoms of Parkinson's, affecting up to 40% of patients. It is clinically distinct from depression, although the two conditions can co-exist and are often confused. A person with apathy may not feel sad — they simply feel nothing, and lack the drive to initiate activities, conversations, or plans. They may show reduced emotional reactivity, appearing indifferent to events that would normally elicit joy, sadness, or concern.

Apathy results from disruption of the dopamine-mediated reward and motivation circuits in the brain, particularly the mesocorticolimbic pathway connecting the ventral tegmental area to the prefrontal cortex and nucleus accumbens. It can be the most distressing symptom for family members and caregivers, who may misinterpret it as laziness, indifference, or a deliberate choice.

Distinguishing Apathy from Depression

• Apathy without depression: Lack of motivation and initiative, but no sadness, hopelessness, or negative self-evaluation. The person does not feel distressed about their lack of motivation — they simply do not feel driven.
• Depression without apathy: Sadness, hopelessness, guilt, and worthlessness, but the person may still want to do things even though they feel overwhelmed or unable.
• Both together: Approximately 30% of people with Parkinson's have both apathy and depression simultaneously, which requires addressing each condition independently.

Approaches for Managing Apathy

• Optimizing dopaminergic medication, as apathy can worsen during "off" states when dopamine levels drop.
• Establishing structured daily routines that reduce the need for self-initiation.
• Setting small, achievable goals to rebuild a sense of accomplishment.
• Engaging in social activities, even when motivation is low, as social interaction can help activate reward pathways. A family member or friend who provides gentle encouragement and initiates activities can be invaluable.
• Exercise — particularly group exercise classes — addresses both the neurochemical and social components of apathy.

Impulse Control Disorders

Impulse control disorders (ICDs) are medication-induced behavioral changes that affect an estimated 13% to 14% of people taking dopamine agonists (pramipexole, ropinirole, rotigotine), according to a landmark cross-sectional study of 3,090 patients published in Archives of Neurology (2010). These disorders are important to recognize because they can cause devastating financial, relational, and personal consequences.

The most common impulse control disorders in Parkinson's include:

• Compulsive gambling — The most frequently reported ICD. Can range from excessive lottery ticket purchases to significant casino losses.
• Compulsive shopping — Acquiring unnecessary items, often concealed from family members. Online shopping has made this more accessible.
• Hypersexuality — Compulsive sexual behavior, excessive demand for sex, or preoccupation with sexual thoughts that is out of character.
• Binge eating — Consuming large quantities of food, particularly sweets or carbohydrates, often at night.
• Punding — A repetitive, purposeless behavior such as sorting, organizing, disassembling objects, or hoarding.
• Dopamine dysregulation syndrome — Compulsive use of dopaminergic medications beyond what is needed for motor symptom control.

The primary treatment is reducing or discontinuing the dopamine agonist, which typically resolves the behavior. However, this must be done gradually and under close medical supervision, as abrupt withdrawal can cause dopamine agonist withdrawal syndrome (DAWS) — a severe condition characterized by anxiety, panic attacks, depression, irritability, and pain. If you or your family notice any of these behaviors, report them to your neurologist immediately. Early detection prevents the most serious consequences.

Cognitive Changes

Cognitive impairment in Parkinson's exists on a spectrum. A 2025 review in Nature Reviews Neurology found that mild cognitive impairment (PD-MCI) affects 24% to 31% of people with Parkinson's at diagnosis. PD-MCI may not significantly interfere with daily life, though it may be noticeable to the person and their family. Over time, roughly 50% to 80% of people with Parkinson's will develop Parkinson's disease dementia (PDD), typically in the later stages.

The cognitive domains most commonly affected include:

• Executive function — Planning, organizing, multitasking, and problem-solving may become more difficult. This is often the earliest cognitive change detected.
• Attention — Sustaining focus, dividing attention between tasks, and processing speed may decline. Fluctuating attention (better and worse periods within the same day) is characteristic.
• Visuospatial skills — Judging distances, navigating spaces, and recognizing objects or faces can be affected.
• Memory — Retrieval of stored memories is more commonly affected than the ability to form new memories (unlike Alzheimer's disease). Giving cues or hints often helps the person recall information.

Strategies for Managing Cognitive Changes

• Using calendars, lists, phone reminders, and pill organizers to support memory and organization. Smart home devices can provide voice-activated reminders.
• Simplifying daily routines and reducing decisions where possible. Consistent routines reduce cognitive load.
• Engaging in cognitively stimulating activities — reading, puzzles, social conversation, learning new skills, music, and art.
• Regular aerobic exercise, which has demonstrated cognitive benefits in Parkinson's. Mind-body exercises such as tai chi and yoga appear to provide particularly strong cognitive benefits.
• Cholinesterase inhibitors (rivastigmine) are FDA-approved for Parkinson's disease dementia and may provide modest improvements in attention, memory, and daily function.
• Treating depression, anxiety, and sleep disorders, all of which worsen cognitive function when left untreated.

Hallucinations and Psychosis

Visual hallucinations occur in up to 50% of people with Parkinson's, especially in later stages. They often begin as benign "passage hallucinations" — sensing someone passing in peripheral vision, seeing shadows move, or brief illusions. These may progress to formed hallucinations of people, animals, or objects that the person recognizes are not real (retained insight). In more advanced cases, insight may be lost and delusions (false beliefs, particularly paranoid delusions about a spouse's infidelity or theft by caregivers) may develop.

Hallucinations are caused by a combination of the disease itself (Lewy body pathology in visual cortex and brainstem) and side effects of Parkinson's medications, particularly dopamine agonists and anticholinergic drugs. Risk factors include older age, longer disease duration, cognitive impairment, depression, and sleep disorders.

Management follows a stepwise approach:

• Medication review — Reducing or stopping medications in order of risk: anticholinergics first, then amantadine, then dopamine agonists, then COMT inhibitors, and levodopa last. Each reduction is balanced against motor symptom worsening.
• Pimavanserin (Nuplazid) — The only FDA-approved medication specifically for Parkinson's disease psychosis. It works through serotonin 5-HT2A inverse agonism and does not worsen motor symptoms.
• Quetiapine — An atypical antipsychotic used off-label at low doses. Less evidence than pimavanserin but sometimes preferred for its sedating properties at bedtime.
• Clozapine — The most effective antipsychotic for Parkinson's psychosis but requires regular blood monitoring due to the risk of agranulocytosis. Reserved for refractory cases.

Never use typical antipsychotics (haloperidol, chlorpromazine) or most atypical antipsychotics (risperidone, olanzapine) in people with Parkinson's — these block dopamine receptors and can cause severe, potentially life-threatening worsening of motor symptoms.

When to Seek Help

Mental health symptoms in Parkinson's are common, treatable, and nothing to be ashamed of. Talk to your neurologist if:

• You feel persistently sad, anxious, or unmotivated for more than two weeks.
• Mental health symptoms are interfering with your daily activities or relationships.
• You or your family notice changes in thinking, memory, or behavior.
• You are experiencing hallucinations, especially if they are frightening or you are losing awareness that they are not real.
• You or your family notice new impulsive behaviors (gambling, shopping, eating, sexual) after starting or increasing dopamine agonist medications.
• You have any thoughts of self-harm or suicide — call 988 (the Suicide and Crisis Lifeline) or go to your nearest emergency room immediately.

The Parkinson's Foundation Helpline (1-800-4PD-INFO) provides free, confidential support and referrals to mental health professionals experienced in Parkinson's disease.